Skip to main content

Advertisement

Table 1 JCPyV-DNA q-PCR in plasma, urine and PBMCs samples of 21 MS patients in 1-year follow-up

From: Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study

  Plasma*,** Urine*,** PBMCs*,**  
Pts. STRATIFY JCV® t0† t0 t1 t2 t3 t0 t1 t2 t3 t0 t1 t2 t3 STRATIFY JCV® t3†
MS 1 Pos 2.70   3.26          3.03 Pos
MS 2 Pos 2.85 2.67 / /    / /   2.56 / / Pos
MS 3 Neg      3.7 3.48 6.01 3.86      Pos
MS 4 Neg     3.15     3.32      Pos
MS 5 Neg      4.1 4.58 7.30 6.18      Pos
MS 6 Neg     2.68          Pos
MS 7 Neg         5.47      Pos
MS 8 Neg         4.74      Pos
MS 9 Neg              Neg
MS 10 Neg              Neg
MS 11 Neg        3.77       Neg
MS 12 Neg           3.72    Neg
MS 13 Neg              Neg
MS 14 Neg              Neg
MS 15 Neg              Neg
MS 16 Neg              Neg
MS 17 Neg              Neg
MS 18 Neg     3.00          Neg
MS 19 Neg   / /    / /    / /   Neg
MS 20 Neg / /    / / 6.04   / /    Neg
MS 21 Neg              Neg
Median JCPyV load** 2.77 2.67 3.26 3.00 3.90 4.03 6.03 4.74   3.14   3.03  
p value§         0.04      
  1. pos: positive; neg: negative.
  2. * 78 urine, 78 plasma and 78 PBMCs samples were collected at baseline (t0) and after 4 (t1), 8 (t2), and 12 (t3) months of therapy.
  3. † 2-step virus-like particle-based enzyme-linked immunosorbed assay (ELISA) (STRATIFY JCV®) was performed at t0 and t3, to detect specific anti-JC virus antibodies in serum of the 21 enrolled subjects.
  4. ** JCPyV loads values are expressed as log10 genome equivalent (gEq)/mL in urine and in plasma, and as log10 gEq/106 cells in PBMCs and they are indicated in boldface.
  5. § By χ2 test: positive STRATIFY JCV® patients after 1-year of natalizumab treatment vs negative STRATIFY JCV® patients after 1 year of natalizumab treatment. p value < 0.05 only for JCPyV DNA positive urine samples.
  6. ‡ patient MS2 suspended natalizumab for allergic reaction; patients MS19 and MS20 showed poor compliance; patient MS18 suspended the biological therapy for uterine cancer and papillomatosis after 11 months of natalizumab infusions; patient MS4 did not perform 2 natalizumab infusions because of Escherichia coli urinary infection; patient MS5 showed clinical relapse during follow up.